Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
SGO 2024 Annual Meeting on Womens Cancer
2024 Multidisciplinary Head and Neck Cancers Symposium
2024 ASCO GU Cancers Symposium
2024 ASCO GI Cancers Symposium
2023 ASH
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
2013 NCCN Annual Conference,2013 NCCN Annual Conference
«
1
»
Advertisement
Advertisement
Mar
19
Today In Oncology
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL New Efficacy Analysis
Localized or Advanced Prostate Cancer Short- or Longer-Term Relugolix Plus Radiotherapy
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
View More
Advertisement